Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

RCT (n=263 after partial or complete response to 12 weeks of taxane platinum combination chemotherapy) found once weekly oral selinexor did not improve progression free survival vs placebo in the intention to treat population (5.7 vs 3.8 months, HR 0.76, p=0.126)

SPS commentary:

Authors note, that patients with the TP53 wild-type endometrial cancer had a median progression free survival of 13.7 and 3.7 months with selinexor and placebo respectively (not a pre-specified endpoint, so not statistically tested).

Journal of Clinical Oncology